Literature DB >> 27326890

Molecular and Epigenetic Biomarkers in Luminal Androgen Receptor: A Triple Negative Breast Cancer Subtype.

Gaëlle Judes1,2, Aslihan Dagdemir1,2, Seher Karsli-Ceppioglu1,2,3, André Lebert4, Marie-Mélanie Dauplat2,5, Khaldoun Rifaï1,2, Marine Daures1,2, Lucas Dubois1,2, Yves-Jean Bignon1,2, Frédérique Penault-Llorca2,5, Dominique Bernard-Gallon1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27326890     DOI： 10.1089/omi.2016.0029

Source DB:  PubMed          Journal:  OMICS        ISSN： 1536-2310


× No keyword cloud information.
  2 in total

Review 1.  Higher order genomic organization and epigenetic control maintain cellular identity and prevent breast cancer.

Authors:  A J Fritz; N E Gillis; D L Gerrard; P D Rodriguez; D Hong; J T Rose; P N Ghule; E L Bolf; J A Gordon; C E Tye; J R Boyd; K M Tracy; J A Nickerson; A J van Wijnen; A N Imbalzano; J L Heath; S E Frietze; S K Zaidi; F E Carr; J B Lian; J L Stein; G S Stein
Journal:  Genes Chromosomes Cancer       Date:  2019-03-15       Impact factor: 5.006

2.  Lack of both androgen receptor and forkhead box A1 (FOXA1) expression is a poor prognostic factor in estrogen receptor-positive breast cancers.

Authors:  Seho Park; Eunjin Koh; Ja Seung Koo; Seung Il Kim; Byeong-Woo Park; Kyung-Sup Kim
Journal:  Oncotarget       Date:  2017-09-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.